Stay updated on LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2Fdt2A9y3fQfKfU8tLGTb0LbkZM-I.uncropped.jpg&w=3840&q=75)
Latest updates to the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page
- Check2 days agoChange DetectedThe LAVA-051 clinical trial has been terminated due to a strategic business decision, not safety concerns, and the trial's scope has shifted from a Phase 1/2a to a Phase 1 trial focused on patients with relapsed or refractory CLL, MM, or AML.SummaryDifference11%
- Check10 days agoChange DetectedDifference1%
- Check17 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference1%
- Check24 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference2%
- Check31 days agoChange DetectedDifference0.9%
- Check38 days agoChange DetectedDifference0.5%
Stay in the know with updates to LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAVA-051 in Relapsed/Refractory Hematologic Malignancies Clinical Trial page.